Suenaga M, Sugiura H, Kokuba Y, Kurumiya T, Yamanaka H, Hatsuno T, Nobuta T
Surgical Service, Nagoya Memorial Hospital.
Gan To Kagaku Ryoho. 1995 Jan;22(1):45-51.
Hepatocellular carcinoma is a refractory cancer for the following two reasons: the tumor characteristics, including formation of tumor thrombus in the portal vein, metastasis within the liver and multicentricity of growth; and liver function disturbance due to cirrhotic change by B- or C-type viral infection. The most desirable treatment is hepatic resection, the only method producing a disease-free condition. However, there are not many cases that meet the indications for hepatic resection, since they have advanced lesions and/or liver dysfunction. If one cannot perform a hepatic resection, other suitable therapies should be selected, including transcatheter arterial embolization, percutaneous ethanol injection therapy, ligation of hepatic artery, irradiation, chemotherapy from hepatic artery via reservoir and so on. Combined therapy may sometimes be necessary for satisfactory efficacy. For long-term survival it is very important to do a close follow-up study over a long period. This encourages us to detect new lesions earlier and then perform suitable therapy again. Notifying patients of the disease and obtaining informed consent are needed for this long-term follow-up and treatment. When patients were examined who had first undergone hepatic resection and then hepatic re-resection for recurrence, we found that their survival rate was not different from that in the non-recurrent cases. This result indicates that overcoming refractory hepatocellular carcinoma requires a multidisciplinary treatment in which hepatic resection is the main means.
肝细胞癌是一种难治性癌症,原因如下:一是肿瘤特征,包括门静脉内肿瘤血栓形成、肝内转移和多中心生长;二是B型或C型病毒感染导致肝硬化改变引起的肝功能障碍。最理想的治疗方法是肝切除,这是唯一能产生无病状态的方法。然而,符合肝切除适应症的病例并不多,因为他们存在晚期病变和/或肝功能障碍。如果无法进行肝切除,应选择其他合适的治疗方法,包括经导管动脉栓塞术、经皮乙醇注射疗法、肝动脉结扎术、放疗、通过储液器经肝动脉化疗等。有时可能需要联合治疗以获得满意疗效。为实现长期生存,长期密切随访研究非常重要。这促使我们更早地发现新病变,然后再次进行合适的治疗。进行这种长期随访和治疗需要告知患者病情并获得知情同意。当检查那些首次接受肝切除然后因复发接受再次肝切除的患者时,我们发现他们的生存率与未复发患者的生存率没有差异。这一结果表明,克服难治性肝细胞癌需要以肝切除为主要手段的多学科治疗。